| 摘要 |
Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation, ligand binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombastenia is charac- terized as having a ligand binding defect. In another embodiment, a patient with myelofibrosis is identified as having an activa- tion defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described which comprise antibodies suitable for characterizing the above defects.
|
